Biovitrum to Present at JPMorgan’s 26th Annual Healthcare Conference
Stockholm, Sweden, January 3, 2008. On January 7, Dr Martin Nicklasson, the CEO of the Swedish biopharma company Biovitrum is scheduled to present at JPMorgan’s 26th Annual Healthcare Conference at the Westin St Francis Hotel in San Francisco, CA.
The presentation will include an update on Biovitrum’s project portfolio, including three projects in clinical Phase II studies: A2A, for the treatment of neuropathic pain; 5-HT2a, for the treatment of glaucoma; and Kiobrina(TM), a novel treatment of pre-term malabsorption. All in all, Biovitrum has nine projects in clinical studies, and a further seven in pre-clinical studies. In addition, Biovitrum has seven products already on the market.
The audio and slide presentation will be webcasted live and can be accessed via Biovitrum’s web site. To access the live and replay presentations, please go to www.biovitrum.com .
The presentation will take place on January 7, 2008, at 11.00 am US Western Time / 8.00 pm Central European Time.
Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for conditions that affect smaller patient populations and for common diseases. Biovitrum has currently a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for a number of well defined specialist indications as well as for common diseases within obesity, diabetes, inflammation, eye and blood diseases. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and around 500 employees. Biovitrum’s share is listed on the OMX Nordic Exchange in Stockholm since September 15, 2006. For more information see http://www.biovitrum.com.
- Contact Information
- Göran Arvidson
- Biovitrum AB
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.